ISABELLA BOLOGNINO

Dr. ISABELLA BOLOGNINO

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2019 in Molecules
Verified
Journal Article
Open access
PDF file
IBISABELLA BOLOGNINO
ISABELLA BOLOGNINO
NGNicola Giangregorio
Nicola Giangregorio
Leonardo PisaniLeonardo Pisani
Leonardo Pisani
Modesto de CandiaModesto de Candia
Modesto de Candia
Rosa PurgatorioRosa Purgatorio
Rosa Purgatorio
MCMarco Catto
Marco Catto
The orphan drug dantrolene (DAN) is the only therapeutic treatment for malignant hyperthermia (MH), a pharmacogenetic pathology affecting 0.2 over 10,000 people in the EU. It acts by inhibiting ryanodine receptors, which are responsible for calcium recruitment in striatal muscles and brain. Because of its involvement in calcium homeostasis, DAN has been successfully investigated for its potential as neuroprotecting small molecule in several animal models of Alzheimer’s disease (AD). Nevertheless, its effects at a molecular level, namely on putative targets involved in neurodegeneration, are still scarcely known. Herein, we present a prospective study on repurposing of DAN involving, besides the well-known calcium antagonism, inhibition of monoamine oxidase B and acetylcholinesterase, cytoprotection from oxidative insult, and activation of carnitine/acylcarnitine carrier, as concurring biological activities responsible for neuroprotection.

7 August 2019 in Proceedings
Verified
Conference Paper
Open access
PDF file
IBISABELLA BOLOGNINO
ISABELLA BOLOGNINO
MCMarco Catto
Marco Catto
Leonardo PisaniLeonardo Pisani
Leonardo Pisani
SCSaverio Cellamare
Saverio Cellamare
Cosimo D. AltomareCosimo D. Altomare
Cosimo D. Altomare
NGNicola Giangregorio
Nicola Giangregorio
Dantrolene is an orphan drug representing the sole therapeutic treatment for malignant hyperthermia, a life-threatening pathology affecting 0.2 in every 10,000 people in the EU.